Since joining Kirkland & Ellis, Kelly has been involved in the following representative matters:
- The joint sponsors, Morgan Stanley Asia Limited, CITIC Securities (Hong Kong) Limited and Goldman Sachs (Asia) L.L.C., and underwriters on the HK$10.68 billion initial public offering and listing of Muyuan Foods Co., Ltd. (SZ: 002714; HKSE: 2714) on the Main Board of the Hong Kong Stock Exchange on February 6, 2026
Prior to joining Kirkland & Ellis, Kelly was involved in the following representative matters:
- The joint sponsors and the underwriters on the global offering and listing of CF PharmTech, Inc. (HKSE: 2652) on the Main Board of the Hong Kong Stock Exchange. The Hong Kong public offering tranche was oversubscribed by approximately 6,700 times, ranking among the top three most oversubscribed IPOs on the HKEx in 2025.
- Cirrus Aircraft Limited (HKSE: 2507), a personal aviation aircraft developer, on its global offering and listing on the Main Board of the Hong Kong Stock Exchange
- The joint sponsors and the underwriters on the global offering and listing of HighTide Therapeutics, Inc. (HKSE: 2511) on the Main Board of the Hong Kong Stock Exchange
- The selling shareholder in connection with the global offering and listing of Beauty Farm Medical and Health Industry Inc. (HKSE: 2373) on the Main Board of the Hong Kong Stock Exchange
- LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (HKSE: 2291) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange
